Granulocyte colony-stimulating factor: Difference between revisions
imported>Howard C. Berkowitz No edit summary |
imported>Howard C. Berkowitz No edit summary |
||
| Line 4: | Line 4: | ||
It is a [[glycoprotein]] containing disulfide bonds, which has a molecular weight of 25 kilodalton (kDa) Among the family of colony-stimulating factors, G-CSF is the most potent inducer of terminal differentiation to granulocytes and macrophages of leukemic myeloid cell lines.<ref>{{MeSH}}</ref> | It is a [[glycoprotein]] containing disulfide bonds, which has a molecular weight of 25 kilodalton (kDa) Among the family of colony-stimulating factors, G-CSF is the most potent inducer of terminal differentiation to granulocytes and macrophages of leukemic myeloid cell lines.<ref>{{MeSH}}</ref> | ||
It is not the same agent as [[granulocyte-macrophage colony-stimulating factor]] (GM-CSF) | It is not the same agent as [[granulocyte-macrophage colony-stimulating factor]] (GM-CSF). | ||
==Medical indications== | ==Medical indications== | ||
Labeled as approved uses by the U.S. [[Food and Drug Administration]]:<ref>{{citation | Labeled as approved uses by the U.S. [[Food and Drug Administration]]:<ref>{{citation | ||
Revision as of 14:56, 30 July 2010
Granulocyte colony-stimulating factor (G-CSF), or filgrastim, is a glycoprotein of MW 25 kDa, which stimulate the production of neutrophils and their precursors, and is used to treat neutropenia. In the United States, it is approved as Neupogen brand of filgrastim.
It is a glycoprotein containing disulfide bonds, which has a molecular weight of 25 kilodalton (kDa) Among the family of colony-stimulating factors, G-CSF is the most potent inducer of terminal differentiation to granulocytes and macrophages of leukemic myeloid cell lines.[1]
It is not the same agent as granulocyte-macrophage colony-stimulating factor (GM-CSF).
Medical indications
Labeled as approved uses by the U.S. Food and Drug Administration:[2] Chemotherapy-induced neutropenia, congenital neutropenia, cyclic neutropenia, idiopathic neutropenia, Neutropenia Secondary to AML Treatment, Prevention of Neutropenia from Cancer Chemotherapy, progenitor cell Enhancement, severe chronic neutropenia
Unlabeled Uses: AIDS-associated neutropenia, drug-induced neutropenia, myelodysplastic syndrome, myeloid engraftment enhancement
References
- ↑ Anonymous (2024), Granulocyte colony-stimulating factor (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Neupogen Inj: Doses and Indications, American Society for Health System Pharmacists/Medscape